Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.

BACKGROUND: Accurate staging is of major importance to determine the optimal treatment modality for patients with prostate cancer. Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) is a promising technique that outperformed conventional imaging in the detection of nodal and distant metastases in previous studies. However, it is still unclear whether the superior sensitivity and specificity also translate into improved patient management. The aim of this study was to assess the performance of 68Ga-PSMA-11 PET for staging of intermediate and high-risk prostate cancer and its potential impact on disease management. METHODS: In this retrospective analysis, 116 patients who underwent 68Ga-PSMA-11 PET/CT or MRI scans for staging of their intermediate or high-risk prostate cancer between April 2016 and May 2018 were included. The potential impact of 68Ga-PSMA-11 PET staging on patient management was assessed within a simulated multidisciplinary tumour board where hypothetical treatment decisions based on clinical information and conventional imaging alone was determined. This treatment decision was compared with the treatment recommendation based on clinical information and 68Ga-PSMA-11 PET imaging. RESULTS: The primary tumour was positive on 68Ga-PSMA-11 PET in 113 patients (97%). Nodal metastases were detected in 28 patients (24%) and bone metastases in 14 patients (12%). Compared with clinical staging and conventional imaging, 68Ga-PSMA-11 PET resulted in new information in 42 of 116 patients (36%). In 32 of 116 patients (27%), this information would most likely have changed the management into a different therapy modality (15 patients, 13%) or adjusted treatment details (e.g. modification of radiotherapy field or lymph node dissection template; 17 patients, 14%). CONCLUSION: Information from 68Ga-PSMA-11 PET staging has the potential to change the management in more than a fourth of the patients who underwent PET staging for their intermediate to high-risk prostate cancer. Whether these more personalized 68Ga-PSMA-11 PET-based treatment decisions will improve patient outcome needs further investigation.

High-resolution diffusion tensor imaging of prostate cancer using a reduced FOV technique.

OBJECTIVE: Diffusion tensor imaging (DTI) offers the promise of improved tumor localization in prostate cancer but the technique suffers from susceptibility-induced artifacts that limit the achievable resolution. The present work employs a reduced field-of-view technique that enables high-resolution DTI of the prostate at 3T. Feasibility of the approach is demonstrated in a clinical study including 26 patients and 14 controls. MATERIALS AND METHODS: Reduced field-of-view acquisition was established by non-coplanar application of the excitation and the refocusing pulse in conjunction with outer volume suppression. Accuracy for cancer detection of apparent diffusion coefficient (ADC) mapping and T2-weighted imaging was calculated and compared with reference to the findings of trans-rectal ultrasound-guided octant biopsy. Mean ADCs and fractional anisotropy (FA) values in the patients with positive and negative biopsies were compared to each other and to the controls. RESULTS: Fine anatomical details were successfully depicted on the ADC maps with sub-millimeter resolution. Accuracy for prostate cancer detection was 73.5% for ADC maps and 71% for T2-weighted images, respectively. Cohen's kappa (κ=0.48) indicated moderate agreement of the two methods. The mean ADCs were significantly lower, the FA values higher, in the patients with positive biopsy than in the patients with negative biopsy and the controls. Monte Carlo simulations showed that the FA values, but not the ADCs, were slightly overestimated. Bootstrap analysis revealed that the ADC, but not the FA value, is a highly repeatable marker. CONCLUSION: In conclusion, the present work introduces a new approach for high-resolution DTI of the prostate enabling a more accurate detection of focal tumors especially useful in screening populations or as a potential navigator for image-guided biopsy.